Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mani-inc" target="_blank" data-smartkarma-citation="entities:6534:1" rel="noopener">Mani Inc (7730 JP)</a> reported Q2FY22 revenue ahead of guidance, mainly driven by demand recovery in the surgical segment and positive effect of foreign exchange. However, profitability declined year-over-year.</li>
<li>Despite revenue beat in H1FY22, management reiterated FY22 guidance due to geographical risk. Outlook seems to be uncertain for China and India, which together contribute 33% of total revenue.</li>
<li>Mani shares plunged 20% since I published bearish note on the company in January 2022. Investors should avoid Mani due to its uncertain revenue outlook and deteriorating profitability in short-term.</li>
</ul>



Mani Inc (7730 JP) reported Q2FY22 revenue ahead of guidance, mainly driven by demand recovery in the surgical segment and positive effect of foreign exchange. However, profitability declined year-over-year.
Despite revenue beat in H1FY22, management reiterated FY22 guidance due to geographical risk. Outlook seems to be uncertain for China and India, which together contribute 33% of total revenue.
Mani shares plunged 20% since I published bearish note on the company in January 2022. Investors should avoid Mani due to its uncertain revenue outlook and deteriorating profitability in short-term.


Mani Inc (7730 JP): Q2 Result Exceeds Expectation Aided by Demand Recovery; FY22 Guidance Reiterated

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mani-inc" target="_blank" data-smartkarma-citation="entities:6534:1" rel="noopener">Mani Inc (7730 JP)</a> shares have plunged 19% since we have published our bearish insight on the company on January 13.</li>
<li>FY22 guidance implies 22% and 56%, y/y, decline in operating profit and profit attributable to owners of parent, respectively, in Q2FY22.</li>
<li>We are cautious on H2FY22 recovery and financial performance of Mani due to worsening COVID-19 condition in China, which is one of its major markets.</li>
</ul>



Mani Inc (7730 JP) shares have plunged 19% since we have published our bearish insight on the company on January 13.
FY22 guidance implies 22% and 56%, y/y, decline in operating profit and profit attributable to owners of parent, respectively, in Q2FY22.
We are cautious on H2FY22 recovery and financial performance of Mani due to worsening COVID-19 condition in China, which is one of its major markets.


Mani (7730 JP): Profit to Decline in Q2; China’s Worsening COVID Outbreak to Weigh on H2 Performance

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Index Rebalance

<ul>
<li>There are 8 additions to the MVIS Vietnam Index at the upcoming rebalance at the close on 18 March. Moderate impact on most of the adds.</li>
<li>There are some stocks that have large float changes; watch <a href="https://www.smartkarma.com/entities/saigon-thuong-tin-commercial" target="_blank" data-smartkarma-citation="entities:650:1" rel="noopener">Saigon Thuong Tin Commercial (STB VN)</a>. Over 1 day of ADV to sell on some stocks due to capping changes.</li>
<li>At the December rebalance, all 5 adds jumped the day post announcement and then stayed in a range till implementation of the changes.</li>
</ul>


There are 8 additions to the MVIS Vietnam Index at the upcoming rebalance at the close on 18 March. Moderate impact on most of the adds.
There are some stocks that have large float changes; watch Saigon Thuong Tin Commercial (STB VN). Over 1 day of ADV to sell on some stocks due to capping changes.
At the December rebalance, all 5 adds jumped the day post announcement and then stayed in a range till implementation of the changes.


MVIS Vietnam Index Rebalance: Eight Additions & Some Big Float Changes

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mani-inc" target="_blank" data-smartkarma-citation="entities:6534:1" rel="noopener">Mani Inc (7730 JP)</a> offers medical devices, which are mainly used in the elective procedures including cataract surgery and dental procedures.</li>
<li>In FY21, the company missed its guidance for both revenue and operating income by 2% and 5%, respectively, due to higher-than-expected impact of the COVID-19.</li>
<li>With the rising cases of highly infectious Omicron variant of the COVID-19 in major operating regions, the company is expected to miss or lower its FY22 guidance.</li>
</ul>



Mani Inc (7730 JP) offers medical devices, which are mainly used in the elective procedures including cataract surgery and dental procedures.
In FY21, the company missed its guidance for both revenue and operating income by 2% and 5%, respectively, due to higher-than-expected impact of the COVID-19.
With the rising cases of highly infectious Omicron variant of the COVID-19 in major operating regions, the company is expected to miss or lower its FY22 guidance.


Mani Inc (7730 JP): No Immediate Respite Seen

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Thematic (Sector/Industry)

<p style="text-align: center;"><strong>• LEADING INDICATOR •</strong></p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/164/379/original/2020-10-10_12-16-59.png?1602299856" class="editor-image img-responsive" data-smartkarma-image-id="164379"></figure><div class="content-caption">Source for all charts &amp; tables: Japan Analytics</div><p><strong>LEADING THE WAY</strong> - The market continues to make new post-COVID highs supported by global and local liquidity conditions and now a bottoming of earnings momentum. As was the case in 2009, the Cabinet Office Leading Indicator, which is published with a lag of two months, identified the low point ahead of the market and our Results &amp; Revision Score. At present, only three Sectors - Internet Content &amp; Services, Information Technology, and Non-Bank Finance have positive Scores, of which only the first and last are rising. We expect the coming 'wave' of announcements to turn the tide as has been 'previewed' in the percentages of positive results and revision over the last week.    </p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/164/382/original/2020-10-10_12-48-29.png?1602301755" class="editor-image img-responsive" data-smartkarma-image-id="164382"></figure><div><p style="text-align: center;"><strong>• BEST &amp; WORST •</strong></p></div><div>
<p>The best and worst pair from yesterday's announcements is <a href="https://www.smartkarma.com/entities/sakata-seed-corp" target="_blank" data-smartkarma-citation="entities:9825:1" rel="noopener">Sakata Seed (1377 JP)</a>  and dental, surgical and ophthalmic instrument maker <a href="https://www.smartkarma.com/entities/mani-inc" target="_blank" data-smartkarma-citation="entities:6534:1" rel="noopener">Mani (7730 JP)</a>. the latter despite the company's very bullish fully-year forecast. </p>
<section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/164/515/original/2020-10-11_11-27-17.png?1602383275" class="editor-image img-responsive" data-smartkarma-image-id="164515"></figure></section><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/164/516/original/2020-10-11_11-30-09.png?1602383437" class="editor-image img-responsive" data-smartkarma-image-id="164516"></figure><div class="content-caption">Source for all charts &amp; tables: Japan Analytics</div></section><hr>
<div><p style="text-align: center;"><strong>DAILY STATS</strong></p></div>
<hr>
<div><p style="text-align: center;"><strong>26 Quarterly Results</strong></p></div>
<div><ul style="list-style-type: disc;">
<li><p><strong>Results Score:</strong> 58% Positive / 10% Neutral / 32% Negative</p></li>
<li><p><strong>Average Results Score Change:</strong> +2.2 points</p></li>
<li><p><strong>Average % Change in Revenue:</strong> +2.1% Quarter YoY / -4.5% Rolling TTM YoY </p></li>
<li><p><strong>Average Operating Profit Margin Change:</strong> -1.9ppt</p></li>
<li><p><strong>Percentage Making Quarterly Losses:</strong> 18%</p></li>
</ul></div>
<hr>
<div><p style="text-align: center;"><strong>32 Annual • 12 Interim Forecasts/Revisions</strong></p></div>
<div><ul style="list-style-type: disc;">
<li><p><strong>Annual Forecast/Revision Score:</strong> 41% Positive / 6% Neutral / 53% Negative</p></li>
<li><p><strong>Interim Forecast/Revision Score Change:</strong> 42% Positive / 8% Neutral / 50% Negative</p></li>
<li><p><strong>Average Forecast/Revision Score Change:</strong> -2.1 point</p></li>
</ul></div>
</div>

• LEADING INDICATOR •Source for all charts &amp; tables: Japan AnalyticsLEADING THE WAY - The market continues to make new post-COVID highs supported by global and local liquidity conditions and now a bottoming of earnings momentum. As was the case in 2009, the Cabinet Office Leading Indicator, which is published with a lag of two months, identified the low point ahead of the market and our Results &amp; Revision Score. At present, only three Sectors - Internet Content &amp; Services, Information Technology, and Non-Bank Finance have positive Scores, of which only the first and last are rising. We expect the coming 'wave' of announcements to turn the tide as has been 'previewed' in the percentages of positive results and revision over the last week.    • BEST &amp; WORST •
The best and worst pair from yesterday's announcements is Sakata Seed (1377 JP)  and dental, surgical and ophthalmic instrument maker Mani (7730 JP). the latter despite the company's very bullish fully-year forecast. 
Source for all charts &amp; tables: Japan Analytics
DAILY STATS

26 Quarterly Results

Results Score: 58% Positive / 10% Neutral / 32% Negative
Average Results Score Change: +2.2 points
Average % Change in Revenue: +2.1% Quarter YoY / -4.5% Rolling TTM YoY 
Average Operating Profit Margin Change: -1.9ppt
Percentage Making Quarterly Losses: 18%


32 Annual • 12 Interim Forecasts/Revisions

Annual Forecast/Revision Score: 41% Positive / 6% Neutral / 53% Negative
Interim Forecast/Revision Score Change: 42% Positive / 8% Neutral / 50% Negative
Average Forecast/Revision Score Change: -2.1 point



🇯🇵 JAPAN • Results & Revisions 10/​​​​​​​​​​09 - Yaskawa, MANI, OSG, JINS, Sakata Seed

Japan

MANI, INC. manufactures medical goods and equipment.  The Company's products include threads and needles for surgeries, surgical knives for eye surgeries, and dental instruments and equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mani Inc (7730 JP)

Mani Inc (7730 JP): Q2 Result Exceeds Expectation Aided by Demand Recovery; FY22 Guidance Reiterated

I am still bearish on Mani due to its revenue uncertainty caused by high exposure to China. Profitability is expected to decline in second half....

Tina Banerjee

Mani (7730 JP): Profit to Decline in Q2; China’s Worsening COVID Outbreak to Weigh on H2 Performance

China's worsening COIVD-19 outbreak and consequent lockdowns will negatively impact Mani's financial performance in H2FY22, as China is one of the...

Tina Banerjee

MVIS Vietnam Index Rebalance: Eight Additions & Some Big Float Changes

There are 8 additions and quite a few float changes to the MVIS Vietnam Index at the March rebalance. The one-way trade is US$80m and over a day of...

Brian Freitas

Mani Inc (7730 JP): No Immediate Respite Seen

Despite reporting double-digit revenue and operating profit growth in Q1, the company is expected to be negatively impacted by the resurgence of...

Tina Banerjee

🇯🇵 JAPAN • Results & Revisions 10/09 - Yaskawa, MANI, OSG, JINS, Sakata Seed

🇯🇵 JAPAN • Results & Revisions 10/09 - Yaskawa, MANI, OSG, JINS, Sakata Seed________________________________

Campbell Gunn

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Mani Inc (7730 JP): Q2 Result Exceeds Expectation Aided by Demand Recovery; FY22 Guidance Reiterated

I am still bearish on Mani due to its revenue uncertainty caused by high exposure to China. Profitability is expected to decline in second half....

Tina Banerjee

Mani (7730 JP): Profit to Decline in Q2; China’s Worsening COVID Outbreak to Weigh on H2 Performance

China's worsening COIVD-19 outbreak and consequent lockdowns will negatively impact Mani's financial performance in H2FY22, as China is one of the...

Tina Banerjee

MVIS Vietnam Index Rebalance: Eight Additions & Some Big Float Changes

There are 8 additions and quite a few float changes to the MVIS Vietnam Index at the March rebalance. The one-way trade is US$80m and over a day of...

Brian Freitas

Mani Inc (7730 JP): No Immediate Respite Seen

Despite reporting double-digit revenue and operating profit growth in Q1, the company is expected to be negatively impacted by the resurgence of...

Tina Banerjee

🇯🇵 JAPAN • Results & Revisions 10/​​​​​​​​​​09 - Yaskawa, MANI, OSG, JINS, Sakata Seed

🇯🇵 JAPAN • Results & Revisions 10/​​​​​​​​​​09 - Yaskawa, MANI, OSG, JINS, Sakata Seed________________________________

Campbell Gunn

🇯🇵 JAPAN • Results & Revisions 10/09 - Yaskawa, MANI, OSG, JINS, Sakata Seed

🇯🇵 JAPAN • Results & Revisions 10/09 - Yaskawa, MANI, OSG, JINS, Sakata Seed________________________________